Propanc Biopharma Surges After New Pancreatic Cancer Data

By: Quiver PriceTracker

Posted: 2 weeks, 2 days ago / Aug. 27, 2026 2:51 p.m. UTC

PPCB

Propanc Biopharma (PPCB) is up 155.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp rally appears tied mainly to a new company announcement highlighting strong preclinical data for PRP, its lead pancreatic cancer program, and management’s statement that it is accelerating a planned Phase 1b study. The move may also have been amplified by the stock’s very small share count, which can make biotech names react violently to favorable development updates.

Details:

On August 27, the company announced new preclinical pancreatic ductal adenocarcinoma data for PRP, including more than 90% mean tumor growth inhibition versus controls and a more than 2.5-fold improvement in median overall survival in treated animals.

The same release said PRP reduced metastatic burden and altered the tumor microenvironment, while also improving sensitivity of chemo-resistant cells to standard chemotherapy.

Management said it is progressing manufacturing, assay validation, and clinical partnerships for a planned Phase 1b study in roughly 40 to 45 patients, with a clinical trial application expected in the coming months.

A recent definitive information statement also showed only about 3.5 million common shares outstanding as of July 24, 2026, which could help explain why bullish news produced an outsized price swing.

Sources:

Propanc Biopharma, SEC, GlobeNewswire

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$PPCB Hedge Fund Activity

We have seen 4 institutional investors add shares of $PPCB stock to their portfolio, and 8 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS GROUP AG removed 182,614 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $273,921
JANE STREET GROUP, LLC removed 117,662 shares (-82.2%) from their portfolio in Q2 2026, for an estimated $176,493
VIRTU FINANCIAL LLC removed 40,748 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $61,122
TWO SIGMA SECURITIES, LLC removed 25,483 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $67,529
TWO SIGMA INVESTMENTS, LP removed 16,257 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $43,081
SASSICAIA CAPITAL ADVISERS LLC removed 16,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $24,000
XTX TOPCO LTD removed 12,098 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $18,147

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.